Anand Bhaskar
Transaction: 10/08/2026
BUY
Change
+100,000
Price
Not reported
Filing
10/14/2026
Type
BUY
Summit Therapeutics Inc.
SMMT • Biotechnology
$15.56
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$12.11B
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.03Healthy liquidity · 9.87Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Oct 20, 2026, 12:11 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$15.56
Change0.00%
Shares Out778.18M
Market Cap$12.11B
Enterprise Value$11.44B
52W Range12.07 - 29.23
Beta-1.24
P/E-14.14
P/B19.22
P/FCF-29.56
EV/EBITDA-17.71
EV/FCF-27.93
Price$15.56
Change0.00%
Shares Out778.18M
Market Cap$12.11B
Enterprise Value$11.44B
52W Range12.07 - 29.23
Beta-1.24
P/E-14.14
P/B19.22
P/FCF-29.56
EV/EBITDA-17.71
EV/FCF-27.93
Earnings Yield-7.07%
FCF Yield-3.38%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.03
Current Ratio9.87
Quick Ratio9.87
Revenue 5Y-100.00%
Target$29.33
Target Upside88.50%
Target Median$30.00
Target Range16.00 - 41.00
Volume6.14M
Avg Volume5.79M
EPS Surprise0.09
Investment DNA
How strong this company looks for long-term investors
29
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Manageable debt level · 0.03Healthy liquidity · 9.87Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 23 analyst votes · 2026-10-20
83/100
Bullish
Bullish
15
Hold
8
Bearish
0
Price Target
2026-10-19
Low
$16.00
Mean
$29.33
Median
$30.00
High
$41.00
Insider Transactions
Recent executive and insider activity
DUGGAN ROBERT W
Transaction: 06/12/2026
BUY
Change
+3,810,000
Price
$13.12
Filing
06/12/2026
Type
BUY
Zanganeh Mahkam
Transaction: 06/12/2026
BUY
Change
+3,810,000
Price
$13.12
Filing
06/12/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Anand Bhaskar | BUY | +100,000 | Not reported | 10/08/2026 | 10/14/2026 |
| DUGGAN ROBERT W | BUY | +3,810,000 | $13.12 | 06/12/2026 | 06/12/2026 |
| Zanganeh Mahkam | BUY | +3,810,000 | $13.12 | 06/12/2026 | 06/12/2026 |
| Soni Manmeet Singh | BUY | +25,000 | $14.46 | 06/04/2026 | 06/04/2026 |
| Zanganeh Mahkam | BUY | +100,000 | $14.60 | 06/04/2026 | 06/04/2026 |
| DUGGAN ROBERT W | BUY | +100,000 | $14.60 | 06/04/2026 | 06/04/2026 |
| Anand Bhaskar | BUY | +30,000 | $18.83 | 01/08/2026 | 01/12/2026 |
| Cesano Alessandra | BUY | +3,219 | $17.52 | 01/02/2026 | 01/06/2026 |
| Clark Kenneth A | BUY | +17,796 | $17.52 | 01/02/2026 | 01/06/2026 |
| Ronaghi Mostafa | BUY | +35,000 | $17.52 | 01/02/2026 | 01/06/2026 |
| Huber Jeff | BUY | +9,885 | $17.52 | 01/02/2026 | 01/06/2026 |
| Xia Yu | BUY | +35,000 | $17.52 | 01/02/2026 | 01/06/2026 |
| Booth Robert F. | BUY | +7,180 | $17.52 | 01/02/2026 | 01/06/2026 |
| DUGGAN ROBERT W | BUY | +11,232 | $17.52 | 01/02/2026 | 01/06/2026 |
| Zanganeh Mahkam | BUY | +11,232 | $17.52 | 01/02/2026 | 01/06/2026 |
| Zanganeh Mahkam | BUY | +26,680 | $18.74 | 10/21/2025 | 10/23/2025 |
| DUGGAN ROBERT W | BUY | +26,680 | $18.74 | 10/21/2025 | 10/23/2025 |
| Soni Manmeet Singh | BUY | +53,361 | $18.74 | 10/21/2025 | 10/23/2025 |
| Anand Bhaskar | BUY | +26,680 | $18.74 | 10/21/2025 | 10/23/2025 |
| Xia Yu | BUY | +533,617 | $18.74 | 10/21/2025 | 10/23/2025 |